EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.